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Abstract
Background: At the individual level, higher HIV viral load predicts sexual transmission risk. We evaluated San Francisco’s
community viral load (CVL) as a population level marker of HIV transmission risk. We hypothesized that the decrease in CVL
in San Francisco from 2004–2008, corresponding with increased rates of HIV testing, antiretroviral therapy (ART) coverage
and effectiveness, and population-level virologic suppression, would be associated with a reduction in new HIV infections.
Methodology/Principal Findings: We used San Francisco’s HIV/AIDS surveillance system to examine the trends in CVL.
Mean CVL was calculated as the mean of the most recent viral load of all reported HIV-positive individuals in a particular
community. Total CVL was defined as the sum of the most recent viral loads of all HIV-positive individuals in a particular
community. We used Poisson models with robust standard errors to assess the relationships between the mean and total
CVL and the primary outcome: annual numbers of newly diagnosed HIV cases. Both mean and total CVL decreased from
2004–2008 and were accompanied by decreases in new HIV diagnoses from 798 (2004) to 434 (2008). The mean (p=0.003)
and total CVL (p=0.002) were significantly associated with new HIV cases from 2004–2008.
Conclusions/Significance: Reductions in CVL are associated with decreased HIV infections. Results suggest that wide-scale
ART could reduce HIV transmission at the population level. Because CVL is temporally upstream of new HIV infections,
jurisdictions should consider adding CVL to routine HIV surveillance to track the epidemic, allocate resources, and to
evaluate the effectiveness of HIV prevention and treatment efforts.
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Introduction
In individuals, antiretroviral therapy (ART)-mediated virologic
suppression reduces perinatal transmission [1–5] and may reduce
sexual transmission [6–12]. However, it remains unclear whether
increasing HIV testing and the levels of ART uptake can reduce
HIV incidence on a population- level. In some areas of the world,
the widespread introduction of ART that occurred in the late
1990s was accompanied by decreases in new HIV infections as
measured by new HIV diagnoses in surveillance data or HIV
incidence in contemporaneous cohort studies. In Taiwan, for
example, the expansion of ART was associated with a greater than
50% reduction in reported new HIV cases [13]. In Vancouver, a
temporal trend in reduction of median VL among HIV-positive
injection drug users (IDU) in care was observed in parallel to a
reduction in HIV incidence in a cohort study of HIV-negative
IDU [14]. However, in other jurisdictions, risk compensation or
increases in sexual risk behavior with the introduction of ART
may have blunted the preventive effect, a possible explanation for
a rise in HIV incidence among men who have sex with men
(MSM) in San Francisco and elsewhere [15,16]. Indeed, different
modeling approaches using varied assumptions regarding adher-
ence, percent coverage of ART-eligible individuals, survival,
duration of infectiousness, and risk compensation arrive at
different conclusions regarding the net effect of ART on
preventing HIV transmission at the population level [17–22]. In
this paper, we evaluate ‘‘community viral load’’ (CVL) as a
biological marker of ART-mediated virologic suppression and
HIV transmission potential at the population level. The latter
implies the hypothesis that suppressing CVL would reduce
population HIV incidence.
The current new era of highly potent, tolerable ART,[23]
coupled with recent advances in HIV testing technology and
policy changes such as recommendations for routine testing, have
increased the proportion of HIV-infected individuals who are
aware of their diagnosis[24–26] and receiving ART [27–29]. In
San Francisco, the implementation of public health measures[30]
including increasing identification of acute infections[31,32],
simplifying HIV testing procedures [26,33], increasing partner
notification[34,35] and linkage to care[36] has increased both
testing and ART uptake. Both testing frequency and the
proportion of HIV-infected individuals aware of their serostatus
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HIV Behavioral Surveillance (NHBS) surveys [37]. In 2008, 72%
of MSM (the predominant risk group in San Francisco) received
an HIV test in the past 12 months compared to 65% in 2004, with
over half (53%) testing in the past 6 months in 2008 (local
unpublished data from one of the co-authors, McFarland). The
proportion of HIV-positive MSM unaware of their HIV status
decreased from 23% in 2004 to between 20.0% and 15.1% in
2008 (local unpublished data from McFarland). Most (88%) newly
diagnosed individuals were linked to primary care within 3 months
of diagnosis [36]. A greater percentage of HIV-positive persons
were in care in 2008 (78%) as compared to 2004 (71%) [27–29].
Notably, the proportion of people living with AIDS who were
receiving ART increased from 74% in 2005 to 90% in 2008 [29].
However, measures of population-level sexual risk behavior, such
as cases of rectal gonorrhea among MSM, an indicator of
unprotected receptive anal intercourse, increased from 400 in
2004 to 465 in 2008 [29].
Our primary hypothesis is that in the current era of more
effective ART, increased uptake of HIV testing, and improved
linkage to care, a greater number of individuals will be
virologically suppressed, which in turn will lower CVL, and
ultimately reduce new HIV infections. Building on the findings of
Wood et al. that a reduction in median VL among HIV-positive
IDU in care correlated with reduced HIV incidence in a cohort
study of HIV-negative IDU [14], we extended the concept using
San Francisco’s comprehensive, population-based HIV/AIDS
case surveillance system. Using surveillance data, which includes
mandatory laboratory-based reporting of all VL results from
patients diagnosed with HIV, we calculated two measures of CVL,
the mean and total of the most recent VL results. We compared
these CVL measures across populations affected by HIV,
examined their spatial distribution, and assessed the correlation
between CVL and newly diagnosed and reported HIV cases from
2004 to 2008. We also examined temporal correlations between
CVL and population rates of virologic suppression, as well as
estimated HIV incidence.
Methods
Ethics Statement
The Department of Health and Human Services (DHHS)
regulations for the protection of human subjects in 45 CFR
46.101(b)(4) qualifies this research as exempt from IRB review
because it uses existing, de-identified data. Furthermore, the coded
private information was not collected for the current research
project, and the primary investigator and the holder of the data
key entered into an agreement prohibiting the release of the key
under any circumstances. Therefore, according to the University
of California, San Francisco’s Committee on Human Research,
this research is not considered human subjects research and does not
require IRB review or exempt certification.
HIV is a mandatory reportable disease in California. The data
collected for the HIV/AIDS Surveillance registry were part of
routine core public health disease surveillance which includes the
legally mandated reporting of all viral loads. The datasets used for
this study were de-identified prior to analyses, the data were coded
and identifiers were kept separately, and the persons involved in
the analyses did not have access to the ‘‘key’’ to link back to the
names contained in the HIV/AIDS surveillance registry.
Measures and definitions
San Francisco HIV/AIDS Case Surveillance System VL
Data. Systematic VL reporting by laboratories began with the
implementation of mandatory names-based HIV case reporting in
California in April 2006. Subsequently, the San Francisco registry
of HIV/AIDS cases has been validated to include over 95% of all
HIV/AIDS diagnoses in the county [38]. Using a combination of
active (chart review) and passive (electronic and provider-initiated
case reports) surveillance, we collected and examined treatment
history, demographic characteristics, transmission risk, health
insurance status, most recent CD4 count, history of ART
regimen change, hepatitis C infection, engagement in care, and
country of origin for all diagnosed HIV/AIDS cases in San
Francisco. Sequential VL results were recorded prospectively and
retrospectively from the initially reported diagnoses. The datasets
used for the analyses reported here were de-identified.
Community Viral Load. We used the term CVL to refer to
an aggregate biological measure of VL for a particular geographic
location—for example the city of San Francisco or a particular
neighborhood— and for a particular group of people who share
socio-demographic characteristics. Although IDU, MSM, or
specific ethnicities may not necessarily constitute a ‘‘community’’
in the sense of complete social interconnectedness or shared
networks, we used the term to broadly refer to populations defined
by demographic, geographic, or behavioral commonality with the
potential for a higher probability of connections to similar
members of the population, including those through needle-
sharing or sexual partnerships. Individuals were included in the
calculation of mean and total CVL for the subpopulation and
geographic analyses if they had one or more VL between 2005 and
2008 regardless of current treatment status or engagement in care.
This time period was chosen to ensure that we included VL data
from the greatest number of people in the HIV/AIDS surveillance
registry after the institution of both names-based HIV and
electronic VL reporting.
Mean Community Viral Load. We defined mean CVL as
the average of the most recent VL of all reported HIV-positive
individuals in a particular population in each year from 2005 to
2008 for the purpose of exploring mean CVL among sub-
populations and by neighborhood. We then calculated annual
mean CVL from 2004–2008 for examining temporal trends and
associations with virologic suppression, newly reported HIV
infections, and HIV incidence estimates. For individuals with
multiple, repeated VL measures, the most recent VL was used.
Mean CVL is an indicator of the average viral burden for a
particular population of HIV-positive persons, and should reflect
treatment effectiveness and transmission risk under our primary
hypothesis. Furthermore, the mean is a stable and approximately
normal estimate of central tendency in samples as large as ours,
despite the substantial right skewness of viral load values. Median
CVL would also be a robust measure of central tendency, but
could lack a direct relationship to population transmission rates.
For example, in a hypothetical population in which the prevalence
of viral suppression increases from 60% to 80% over 5 years,
median viral load would be below the limit of detection every year
and thus unchanged. In contrast, mean CVL would reflect the
increases in suppression, and has a direct relationship to total
community viral load, possibly a more important population
marker of potential transmission. Specifically, in our dataset,
greater than 50% of individuals had evidence of virologic
suppression from 2004–2008 and thus the median CVL was
,=75 copies/mL annually from 2004–2008; the lack of
variability in the median limited our ability to examine the
relationship between median CVL and new HIV infections.
Total Community Viral Load. We defined total CVL as the
sum of the most recent VL of all reported HIV-positive individuals
in a particular population from 2005–2008 for the geographic
CVL & New HIV Infections
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evaluating the association with population rates of virologic
suppression, new HIV diagnoses, and HIV incidence. The total
CVL serves as a measure of the absolute level of virus in a
population at the most recent point in time, and is therefore a
gauge of potential infectiousness in a particular population. The
measure takes into account both the number of individuals with
HIV/AIDS in a particular population as well as each individual’s
most recent viral load.
New HIV diagnoses. We defined new HIV diagnoses by the
year of the earliest known HIV-positive test result for all HIV/
AIDS cases reported annually from 2004 to 2008. New HIV
diagnoses became reportable by name in California in 2006;
previous code-reported cases were re-reported and reclassified by
name as far back as 2004. We recognize that new HIV diagnoses
may sometimes represent newly diagnosed but chronically infected
individuals, rather than incident HIV infections. Nonetheless,
trends in new HIV diagnoses have been used as a marker for HIV
incidence in previous studies in Taiwan [39] and Australia [40,41],
and have been consistent with trends in estimates of HIV
incidence in San Francisco based on other methods [42].
HIV Incidence. Applying the CDC methods used to estimate
national HIV incidence [43], San Francisco calculated the local
HIV incidence estimates for 2006–2008 [42], which were used as
outcome measures in the present analysis. The time period is
restricted to start in 2006 because San Francisco was funded to
conduct HIV incidence surveillance only after names-based HIV
reporting was adopted in 2006. The method, previously described
in detail [44], estimates HIV incidence based on the number of
recent HIV infections detected by the Serologic Testing Algorithm
for Recent HIV Seroconversion (STARHS) among newly
reported cases in the surveillance system while adjusting for the
likelihood of testing, use of ART, missing specimens, and the
duration of the BED assay window period (within the previous 6
months). The BED and testing history are used to estimate
prevalence among non-testers and impute data for testers to
calculate a population-based incidence estimate. We have
previously reported that the method produced local HIV
incidence estimates comparable to other methods used in San
Francisco [28,29].
Percent Virologic Suppression #75 copies/mL. We
define virologic suppression as having the most recent VL #
75 copies/mL, which was the lower limit of detectability in the
earlier part of the time period analyzed.
Analysis
We conducted two sets of analyses: a cross-sectional period
analysis using all the data from 2005–2008 and longitudinal
analyses using annual data from 2004 to 2008. We used the cross-
sectional data from the time period from 2005 to 2008, to calculate
mean and total CVL for San Francisco as a whole as well as for
sub-populations defined by demographic characteristics, transmis-
sion risk category, clinical factors, and geography. We used
Geographic Information Systems software (ArcGIS v 9.3) to map
the cross-sectional 2005–2008 mean and total CVL data by
neighborhood. Differences in this initial cross-sectional estimate of
mean CVL for various populations were assessed using the
Kruskal-Wallis test. We then calculated the annual measures of
mean and total CVL from 2004 to 2008 and used Poisson models
to assess the relationships between these two annual CVL
measures and newly reported HIV diagnoses in 2004–2008;
robust standard errors, which relax the Poisson assumption that
the variance of the outcome equals its mean, were used to account
for potential over-dispersion. Linear models were used to assess the
relationship of annual measures of mean and total CVL with
population rates of virologic suppression from 2004–2008. We
assessed the relationships between trends in mean and total CVL
and estimated HIV incidence from 2006–2008 using meta-
regression to account for the imprecision of the CDC HIV
Incidence estimates. Analyses were repeated using log-transformed
mean and total CVL, without materially affecting results.
While over 95% of HIV/AIDS diagnoses made in San
Francisco are included in the surveillance database, many
observations have missing data; in particular, VL was only
74.4% complete. We attempted to characterize the individuals
who were missing VLs. Of those 4,312 individuals missing VLs,
4,262 (99%) were not in engaged in care in San Francisco; of
whom 569 could be confirmed to have moved out of the
jurisdiction. One large private medical provider that cares for
3,142 HIV-infected patients in the analysis dataset only reports the
initial diagnosis VL to the HIV/AIDS surveillance registry; 691
individuals seen at this institution were missing VLs. Analyzing
only complete cases may induce bias and wastes information
available from observations with incomplete data. To avoid these
problems, we used SAS Proc MI to multiply impute VL on the log
scale based on race/ethnicity, sex, gender, age at diagnosis,
transmission risk category, insurance status, and neighborhood, as
well as CD4 count, treatment history, AIDS diagnosis, Hepatitis C
co-infection, number of opportunistic infections, history of ART
use, and engagement in care. The ten completed datasets were
then analyzed using SAS Proc MIAnalyze, which combines the
dataset-specific results using established methods that provide
standard errors, confidence intervals, and p-values properly
reflecting imputation of missing data [45]. As a sensitivity analysis,
we conducted multiple imputation to generate VL results
excluding the individuals who had moved out of the jurisdiction.
Results
The overall San Francisco mean CVL was 23,348 copies/mL for
the 12,512 unduplicated HIV-positive individuals reported in the
surveillance database and who had at least one VL during the cross-
sectional analysis time period 2005 through 2008. Table 1 shows
mean CVL for different populations according to reported VL and
with imputation for missing VL (total missing 4,312) for the time
period 2005–2008. Neither the relative mean CVL nor variations in
the mean changed when using the imputed values. Similarly, in the
sensitivity analyses, excluding those who had moved did not change
the mean CVL nor variations in the mean. Remaining findings are
therefore presented using the observed data.
There were statistically significant variations (p,0.001 by
Kruskal-Wallis test) in mean CVL by treatment history, race/
ethnicity, age, gender, HIV transmission risk category, insurance
status, and clinical status. Mean CVL for African-Americans
(26,404 copies/mL; N=1,825; 15%), for Latinos (26,774; N=
1,822; 15%), and for women (27,614 copies/mL; N=786; 6%)
were higher than the overall San Francisco mean CVL.
Transgendered individuals had also had a higher mean CVL
(64,160 copies/mL; N=291, 2%) than the city as a whole. IDU
(33,245 copies/mL; N=1,011; 8%) and MSM-IDU (36,261 cop-
ies/mL; N=1,791; 14%) had higher mean CVL than the overall
mean, whereas MSM (19,596 copies/mL; N=8,997; 72%) had
the lowest. Persons on treatment (18,252 copies/mL; N=9,588;
77%) and those who were engaged in care (15,314 copies/mL;
N=7,875; 63%) had a lower mean CVL than the overall mean
(23,348 copies/mL) and those not currently on treatment
(40,056 copies/mL; N=2,924; 23%) or not engaged in care
(36,992 copies/mL; N=4,637; 37%). Mean CVL was highest
CVL & New HIV Infections
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Variable Subcategory N (%) Mean CVL Kruskal-Wallace Mean CVL, imputed data
Overall 12,512 23,348
Treatment history ,0.001
On treatment 9,588 (77) 18,252 17,200
Not on treatment 2,924 (23) 40,056 44,149
Race/ethnicity ,0.001
White 8,019 (64) 21,087 22,596
African American 1,825 (15) 26,404 30,192
Other
1 846 (7) 30,807 31,577
Latino 1,822 (15) 26,774 27,490
Age in years ,0.001
0–19 96 (1) 33,621 34,542
20–29 2,379 (19) 33,077 33,360
30–39 5,436 (54) 23,348 24,236
40–49 3,473 (21) 18,717 21,161
50–59 951 (7) 15,725 18,997
60+ 177 (1) 18,824 26,663
Sex ,0.001
Male 11,726 (94) 23,062 24,651
Female 786 (6) 27,614 31,234
Transgender ,0.001
Yes 291 (2) 64,160 58,951
No 12,221 (98) 22,376 24,238
Transmission risk ,0.001
IDU 1,011 (8) 33,245 38,592
MSM/IDU 1,791 (14) 36,261 36,764
Other
2 713 (6) 24,221 29,919
MSM 8,997 (72) 19,596 20,799
Insurance status ,0.001
Public 1,568 (13) 26,286 28,661
Private 6,155 (49) 16,577 18,088
None 3,513 (28) 27,936 27,980
Other/Unknown
3 1,276 (10) 39,765 40,497
Most recent CD4 count ,0.001
,50 368 (3) 124,318 128,300
50–199 1,391 (12) 27,052 46,706
200–349 2,547 (21) 23,347 23,316
.=350 7,730 (64) 12,994 13,087
Ever changed regimen ,0.001
Yes 2,167 (17) 18,835 18,637
No 10,345 (83) 24,293 26,015
Hepatitis C ,0.001
Yes 2,347 (19) 27,498 28,669
No 10,165 (81) 22,389 24,368
Engaged in care ,0.001
Yes 7,875 (63) 15,314 15,309
No 4,637 (37) 36,992 33,668
Country of origin 0.0452
US 10,307 (82) 23,812 25,033
Non-US 1,395 (11) 23,428 24,433
Other/Unknown 810 (6) 17,305 26,218
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decreasing as CD4 count increased.
Total CVL reflected mean CVL by population with a notable
exception of geography. The highest mean CVL (38,428 copies/
mL; N=278; 2%) was in the southeast neighborhood of Bayview,
which is characterized by lower income and a predominantly
African-American population (Figure 1a). Homeless persons had
the highest mean viral load (38,974 copies/mL; N=775; 6%).
The northeast and inner city areas of the Tenderloin and South of
Market (characterized by low income and large numbers of IDU,
commercial sex workers, and transgendered persons) also had a
mean CVL above the municipal average (28,093 copies/mL;
N=1,486; 12%). Of note, the Castro neighborhood (an historic
gay and relatively upper-income neighborhood with very high
HIV/AIDS case density) had a mean CVL of 21,352 copies/mL
(N=2,106; 17%), below the city as a whole. The distinction
between mean CVL and total CVL is seen in Figure 1b. The
highest total CVLs are evident in the Tenderloin, South of
Market, Mission, and the Castro, where there are either large
numbers of persons living with HIV, many persons with high VLs,
or a combination thereof.
From 2004 to 2008, there were statistically significant declines
in annual measures of both total (p=0.021) and mean CVL
(p=0.037) as shown in Figure 2 and Figure 3. As expected, there
was an inverse correlation between the increase in virologic
suppression from 45% in 2004 to 78% in 2008 (p=0.006) and
both total CVL (p-0.011, shown in Figure 2) and mean (p=0.013,
not shown). Newly diagnosed cases of HIV decreased in San
Francisco from 798 (2004) to 434 (2008) (p,0.005). The point
estimates of HIV incidence using the CDC methods also declined
from 935 [95% CI 658–1212] in 2006, to 792 [552–1033] in 2007
and 621[462–781] in 2008, although the change was not
statistically significant (trend p=0.29, Figure 3). The reductions
in annual measures of mean CVL were significantly associated
with decreases in newly diagnosed and reported HIV cases from
2004–2008 (p=0.003, shown in Figure 3) as were reductions in
annual measures of total CVL (p=0.002, not shown). Longitudi-
nal reductions in estimated HIV incidence were consistent with
the trends in mean and total CVL, but the association in the meta-
regression was not statistically significant (p.0.3).
Discussion
We found that the decreases in annual measures of mean and
total CVL in San Francisco were significantly associated with
temporal decreases in the number of new HIV diagnoses and
accompanied by a decline in estimated HIV incidence by over
one-third from 2006–2008. Although the trend in reduction of
HIV incidence was not statistically significant, due to several
sources of variation in the estimation, the trend across three
consecutive years is consistent with the parallel and highly
statistically significant decline in newly reported and diagnosed
HIV cases and with trends in several indicators of potential
transmission. A particularly rapid decrease in CVL occurred from
2005 to 2008, a period characterized by an increase in ART
uptake among people living with AIDS from 74%[28] to 90%
Figure 1. Spatial Distribution of CVL by Neighborhood, 2005–2008. Neighborhood mean (1a) and total CVL (1b) are shown. Mean CVL was
highest among homeless individuals (38,974copies/mL; N=775; 6%). The highest mean CVL (38,428 copies/mL; N=278; 2%) was in the southeast
neighborhood of Bayview, which is characterized by lower income and a predominantly African-American population. The northeast and inner city
areas of the Tenderloin and South of Market (characterized by low income and large numbers of IDU, commercial sex workers, and transgendered
persons) also had a mean CVL above the municipal average (28,093 copies/mL; N=1,486; 12%). The Castro neighborhood (an historic gay and
relatively upper-income neighborhood with very high HIV/AIDS case density) had a mean CVL of 21,352 copies/mL (N=2,106; 17%), below the city as
a whole. The distinction between mean CVL and total CVL is seen in 1b. The highest total CVLs are evident in the Tenderloin, South of Market,
Mission, and the Castro, where there are either large numbers of persons living with HIV, many persons with high VLs, or a combination thereof.
doi:10.1371/journal.pone.0011068.g001
1Other race includes Asian, Pacific Islander, Native American, Mixed race, Other, and Unknown.
2Other risk includes sex with female, hemophilia, blood transfusion, heterosexual relations, transplant, occupational, and no identified risk.
3Other/Unknown insurance includes VA, Healthy San Francisco, San Francisco Jail, and unknown insurance status.
doi:10.1371/journal.pone.0011068.t001
Table 1. Cont.
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regimens, and a significant increase in the population rate of
virologic suppression from 46.8% of all HIV/AIDS patients in
2005 to 78.1% by 2008 (Fig. 2). The trends are also concurrent
with changes in laws facilitating HIV testing [26],policy initiatives
promoting expanded HIV testing [25,26], increasing acute HIV
detection [46,47], partner services [34,35], and a reduction in the
rate of unknown HIV infection. Taken together, the findings
support our primary hypothesis that reductions in CVL resulting
from increased ART uptake, expanded ART options, and greater
virologic suppression can in turn reduce HIV incidence at the
population level.
Our analysis also supports the use of CVL as a surveillance
biomarker for treatment effectiveness and HIV transmission risk in
a given jurisdiction or among a group of individuals. Differences in
mean CVL among different groups are consistent with our
understanding of the known disparities in HIV/AIDS morbidity
and mortality in San Francisco, particularly with respect to low-
income neighborhoods, African-Americans, and transgendered
individuals [29,48,49]. The geographic disparities in CVL are
consistent with known disparities in socioeconomic status and may
also reflect neighborhood-level environmental factors [48,50,51]
that structure HIV risk and access to prevention and care, such as
availability of alcohol and drugs, transportation, and proximity to
quality health care programs. These factors may be most evident
in the low-income and relatively isolated Bayview with its very
high mean CVL. As expected, the Castro had the overall highest
total CVL given its high HIV/AIDS case density. Yet, the high
total CVL in the Tenderloin is worthy of further exploration as it
likely reflects both a high number of persons living with HIV
coupled with disparities in any of several factors, including the
uptake of ART, adherence to ART, or engagement in care. Our
findings suggest that targeting HIV prevention to areas with the
greatest total CVL, such as the Castro, should produce the greatest
reductions in overall HIV incidence, while addressing inequities in
both access to care and prevention services should decrease the
relative disparities in HIV incidence among the subpopulations
and in the geographic areas in San Francisco with highest mean
VL.
There are several limitations to our study, including the well-
understood problems with surveillance data. In particular, our
dataset only included HIV-positive individuals who were diag-
nosed and reported in the HIV/AIDS case registry and had at
least one VL measurement between 2005 and 2008. We were not
able to include individuals who are not yet diagnosed. However,
the estimated 15–20% of HIV-positive persons who are unaware
of their infection is lower in San Francisco than the 25% unaware
nationally in 2004 [24]. Our analysis also does not include those
who are diagnosed but not yet reported to the HIV/AIDS case
registry, but this is estimated to be less than 5% of all cases [38].
We also could not include all persons who are acutely infected with
HIV, who may contribute significantly to amplified HIV
transmission [52,53], as many of these individuals are not
diagnosed in the acute stage of infection. Omission of acute
infections would affect the longitudinal trend in mean or total
CVL if (1) acute infections compose a large proportion of the total
number of cases or (2) the rate of new infections rapidly changed.
However, we currently estimate that acute infections comprise a
small minority of all prevalent HIV infections [46,47] in San
Francisco. If we were able to improve the detection of acute HIV
infections and they are as important a part of transmission as
hypothesized by some investigators [52,53], we might even see a
stronger correlation between CVL and incidence rates. The
increase in the correlation would be very slight, however, because
acutely infected persons are a very small minority of the total
population included in CVL. In addition, viral load results were
Figure 2. Total CVL and Virologic Suppression, 2004–2008. There was a statistically significant decline in annual measures of total CVL from
2004–2008 (p=0.021). As expected, there was an inverse correlation between the increase in virologic suppression (red line) from 45% in 2004 to 78%
in 2008 (p=0.006) and total CVL (p=0.011).
doi:10.1371/journal.pone.0011068.g002
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imputation to replace those missing values, but this requires the
strong assumption that the data are missing at random, given the
available covariates. This assumption may not hold, so that the MI
estimate of mean CVL in any given year remains biased.
However, the associations between trends in CVL and new HIV
infections could be approximately unbiased, provided the bias is
comparable across years. Another limitation is that HIV incidence
estimates calculated by the CDC method involve several
imprecisely estimated inputs. For example, not all recent HIV
diagnoses have remnant samples available for BED assay testing,
resulting in an imprecise assessment of recent vs. chronic infection;
similarly, not all cases have HIV testing history reported, which is
needed to adjust incidence estimates. Thus, while point estimates
of HIV incidence declined by over one-third, neither the trend nor
the association with CVL reached statistical significance. In
addition, we did not have the power to examine whether
differences in mean CVL by sub-group were related to disparities
in HIV incidence by sub-group. We also acknowledge the
important possibility of ecologic fallacy. This is an observational
study and there is limited ability to directly assess causality. For
example, we cannot determine if transmissions occur from treated
or untreated individuals. Similarly, the association between
community viral load and new HIV infections could be
confounded by different levels of risk behavior among distinct
sub-populations. Although we lack routinely collected population-
level risk behavior data and could not adjust for that association in
our analysis, we do have data on sexually transmitted diseases,
such as rectal gonorrhea, as a proxy for sexual risk behavior.
Moreover, a decrease in new cases may reflect testing patterns or
risk behavior levels. However, newly diagnosed HIV cases
decreased concurrently with a significant increase in HIV testing
uptake and a reduction in the number of people unaware of their
HIV diagnosis, despite increased cases of rectal gonorrhea. That
new HIV infections declined during a period when sexual risk
behaviors increased, as suggested by increased cases of rectal
gonorrhea, lends further credence to our hypothesis that the
reduction in HIV infections was driven primarily by reductions in
community viral load rather than reductions in sexual risk
behavior. Despite these limitations, we believe our data from
multiple independent sources provide persuasive evidence that the
recent increases in HIV testing, treatment coverage and efficacy,
and viral load suppression are having an effect on the HIV
epidemic, and that CVL is a useful biomarker of these effects. In
summary, reductions in San Francisco mean and total CVL
following comprehensive public health measures to increase HIV
testing and ART uptake were consistent with apparent declines in
HIV incidence and strongly associated with declines in newly
diagnosed HIV infections.
There is current, heated debate on whether ‘‘test and treat’’
strategies can eradicate the HIV epidemic or reduce HIV
incidence at a population level. To be clear, we do not suggest
that our data prove that treatment alone can accomplish these
aims. Rather, we believe achieving a high level of ART coverage is
Figure 3. Mean CVL and New HIV Infections, 2004–2008. There was a statistically significant decline in annual measures of mean CVL from
2004–2008 (p=0.037). Newly diagnosed cases of HIV (shown in red with {) decreased in San Francisco from 798 (2004) to 434 (2008) (p,0.005). The
point estimates of HIV incidence (shown in dark red with n) using the CDC methods also declined from 935 [95% CI 658–1212] in 2006, to 792 [552–
1033] in 2007 and 621 [462–781] in 2008, although the change was not statistically significant (trend p=0.29). The reductions in annual measures of
mean CVL were significantly associated with decreases in newly diagnosed and reported HIV cases from 2004–2008 (p=0.003). Longitudinal
reductions in estimated HIV incidence were consistent with the trends in mean and total CVL, but the association in the meta-regression was not
statistically significant (p.0.3).
doi:10.1371/journal.pone.0011068.g003
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prevention’’ [54] approach incorporating behavioral, biomedical,
public health [55,56] and structural interventions to the HIV
epidemic that has manifest individual health benefits and, we
believe, potential prevention effects. While the relative amounts of
incidence reduction achievable by behavior change interventions
versus VL suppression may be an area of contention, there should
be consensus that both are needed. Given the continued HIV
transmission that occurs in all areas of the world regardless of
whether uptake of ART is high or not, programs intervening on
risky behavior (including both sexual and syringe-sharing) also
need to be scaled up and improved [54,57,58]. And until all of the
estimated 9.7 million persons [59] who need HIV treatment are
able to access ART, the urgency to scale up treatment remains as a
matter of social justice and human rights, regardless of its
prevention effects [60–63].
In the meantime, we recommend that public health depart-
ments and other organizations consider using CVL as an indicator
of the overall success of ART uptake and for HIV prevention
efforts mediated through increased HIV testing, early linkage into
care, improved engagement and retention in care, and increased
virologic suppression. Because CVL is temporally upstream of new
HIV infections, it may be particularly useful as an outcome
measure for multi-level HIV prevention trials or community-level
interventions, including behavioral, ‘‘test and treat,’’ ‘‘ART as
prevention,’’ or earlier ART initiation [64] strategies at the
population level. Additionally, mapping the spatial distribution of
CVL may delineate disparities, new ‘‘hotspots’’ or areas with
particularly high HIV incidence, allowing a rapid response to
target resources and interventions to populations at greatest risk.
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